| Palovarotene, a cytochrome P450 3A4 substrate, is under investigation for the treatment of fibrodysplasia ossificans progressiva (FOP), an ultra-rare genetic disorder |
| Despite known differences in metabolism of cytochrome P450 substrates, this trial demonstrated that palovarotene is metabolized similarly between Japanese and non-Japanese individuals |
| Palovarotene dose adjustments are not necessary for Japanese patients with FOP |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.